Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy similar...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Bonnie K., Gardner, Heather L., Izumi, Raquel, Hamdy, Ahmed, Rothbaum, Wayne, Coombes, Kevin R., Covey, Todd, Kaptein, Allard, Gulrajani, Michael, Van Lith, Bart, Krejsa, Cecile, Coss, Christopher C., Russell, Duncan S., Zhang, Xiaoli, Urie, Bridget K., London, Cheryl A., Byrd, John C., Johnson, Amy J., Kisseberth, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951150/
https://www.ncbi.nlm.nih.gov/pubmed/27434128
http://dx.doi.org/10.1371/journal.pone.0159607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951150/
https://www.ncbi.nlm.nih.gov/pubmed/27434128
http://dx.doi.org/10.1371/journal.pone.0159607

Ejemplares similares